what we fund
We invest by thesis, not by trend. That thesis spans biological discovery to care delivery: AI-driven biopharma technology and services, biological engineering and biomanufacturing, precision medicine, life sciences tools and software, and new models for delivering and paying for care.
We back the platforms that accelerate product development, not the products themselves: no therapeutic assets, no implantable devices.
how we fund
We lead, co-lead, or join syndicates, based on what works best for the company. We reserve capital to follow on. In areas where we share conviction, we even co-found.
